MedTrace Logo

EL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT00636155 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2012-11-28

Study results available
· View outcomes & findings →

Summary

The purpose of this research study is to see if the investigational drug EL625, when combined with traditional chemotherapy (rituximab, fludarabine, and cyclophosphamide), is effective in Persistent Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

Conditions

  • Lymphoma, Small Lymphocytic
  • Leukemia, Lymphocytic, Chronic

Interventions

DRUG

cenersen sodium

2.4 mg/kg/day as a continuous infusion over 24 hours starting on day one and ending on day 4

DRUG

Rituximab

375 mg/m2 on day 2

DRUG

Cyclophosphamide

250 mg/m2 on days 2, 3, and 4

DRUG

Fludarabine

25 mg/m2 on days 2, 3, and 4

Sponsors & Collaborators

  • Eleos, Inc.

    collaborator INDUSTRY

  • David Rizzieri

    lead OTHER

Principal Investigators

  • David Rizzieri, MD · Duke University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2011-08-31
Completion
2012-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00636155 on ClinicalTrials.gov